A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab in Patients With Glioblastoma

Part of paid clinical trials in Cincinnati, Ohio.

Sponsor
Tracon Pharmaceuticals Inc.
Study ID
NCT01564914
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • TRC105 — DRUG
    10 mg/kg weekly by intravenous administration on Days 1, 8, 15 and 22 of each 28-day cycle
  • Bevacizumab — DRUG
    IV

Study Details

The purpose of this study is to evaluate the safety and efficacy of TRC105 in patients with recurrent or progressive glioblastoma after prior antiangiogenic therapy (including anti-VEGF therapy)

Key Dates

First listed
Mar 28, 2012
Start date
May 31, 2012
Status verified
May 2019
Primary completion
Jun 30, 2015
Completion
Jun 30, 2015

Study Design

Enrollment
22 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: TRC105, Bevacizumab
    Single arm study

Primary Outcome Measure

Median Overall Survival (OS) [ Time Frame: 6 Months ]

Locations (4)

FacilityCityStateZIPSite coordinators
University of CincinnatiCincinnatiOhio45267-
Cleveland ClinicClevelandOhio44195-
University Hospitals of ClevelandClevelandOhio44106-
Ohio State UniversityColumbusOhio43210-

Find similar trials in Cincinnati, OH

By condition
Brain cancer
By specialty
OncologyNeuro-oncology
By research site
University of Cincinnati· Cincinnati, OHCleveland Clinic· Cleveland, OHUniversity Hospitals of Cleveland· Cleveland, OHOhio State University· Columbus, OH

Related Studies